Serina Therapeutics, Inc.
SERNYSE
$2.13
↑ +7.6%Jul 17 close · end-of-day
Price
1Y↓ -58.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.7M
Enterprise Value
$1.1M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-71.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$21.3M
Free Cash Flow (TTM)
-$18.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-120.6%
ROIC
—
Debt / Equity
—
Net Cash
$24.5M
Return 1Y
-59.9%
Company profile
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
- CEO
- Steven A. Ledger
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Alabama
- Website
- serinatherapeutics.com
Management & directors
- Ledger Steven AChief Executive Officer
- Moreadith RandallChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
SER Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.58↑ +18.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $361,000.00 | $144,000.00 | $34,000.00 | $3.2M | $56,000.00 | $130,000.00 |
| Gross profit | $335,000.00 | $125,000.00 | $21,000.00 | $102,000.00 | — | — |
| Operating income | -$10.1M | -$7.9M | -$7.0M | -$3.1M | -$17.0M | -$24.0M |
| Net income | -$10.9M | -$8.7M | -$10.5M | $5.3M | -$11.1M | -$19.2M |
| Diluted EPS | — | — | -$9.70 | $0.73 | -$1.51 | -$1.91 |
| Operating cash flow | -$7.8M | -$7.9M | -$5.9M | -$2.5M | -$17.1M | -$18.0M |
| Free cash flow | -$7.8M | — | — | — | -$17.2M | -$18.0M |
| Gross margin | 92.8% | 86.8% | 61.8% | 3.2% | — | — |
| Operating margin | -2797.8% | -5509.0% | -20514.7% | -99.2% | -30442.9% | -18478.5% |
| Net margin | -3009.7% | -6024.3% | -30770.6% | 167.1% | -19894.6% | -14755.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51,000.00 | $14,000.00 | -$14,000.00 | $0.00 | $130,000.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.9M | -$5.3M | -$5.5M | -$5.9M | -$5.6M | -$6.4M | -$6.2M | — |
| Net income | $5.2M | $1.4M | -$2.7M | -$4.8M | -$6.4M | -$4.6M | -$3.3M | -$6.9M |
| Diluted EPS | $0.51 | $0.13 | $3.23 | -$0.49 | -$0.66 | -$0.45 | -$0.31 | -$0.58 |
| Operating cash flow | -$8.0M | -$3.0M | -$4.6M | -$4.3M | -$3.8M | -$3.9M | -$6.0M | -$4.6M |
| Free cash flow | -$8.0M | -$3.0M | -$4.6M | -$4.3M | -$3.8M | -$3.9M | -$6.0M | -$4.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7580.4% | -37942.9% | 39635.7% | — | -4280.8% | — | — | — |
| Net margin | 10203.9% | 10071.4% | 19571.4% | — | -4960.0% | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Brannan Stephen K. | Buy | 1,000 | $2.03 | $2,030.00 | filing |
| 2026-06-17 | Bailey Gregory | C | 6,666,667 | $2.25 | $15.0M | filing |
| 2026-06-17 | Bailey Gregory | C | 1,770,805 | $2.25 | $4.0M | filing |
| 2026-06-17 | Venkatesan Jay | C | 224,152 | $2.25 | $504,342.00 | filing |
| 2026-06-12 | WILSON KAREN J | Buy | 5,000 | $1.77 | $8,850.00 | filing |
| 2026-06-11 | WILSON KAREN J | Buy | 5,100 | $1.75 | $8,899.50 | filing |
| 2026-05-26 | LEDGER STEVEN A· Chief Executive Officer | Award | 10,100 | $1.93 | $19,493.00 | filing |
| 2026-05-22 | WILSON KAREN J | Buy | 10,000 | $1.93 | $19,300.00 | filing |
| 2026-05-22 | Venkatesan Jay | Buy | 589 | $1.78 | $1,048.42 | filing |
| 2026-05-21 | WILSON KAREN J | Buy | 10,000 | $1.77 | $17,700.00 | filing |
| 2026-05-19 | Marshall Richard Peter | Buy | 12,183 | $1.65 | $20,101.95 | filing |
| 2026-03-31 | Bailey Gregory | Award | 59,667 | $1.94 | $115,753.98 | filing |
| 2026-03-31 | Venkatesan Jay | Award | 7,553 | $1.94 | $14,652.82 | filing |
| 2026-03-23 | Moreadith Randall· Chief Scientific Officer | Sale | 6,500 | $2.86 | $18,567.90 | filing |
| 2026-03-23 | Moreadith Randall· Chief Scientific Officer | Option exercise | 6,500 | $0.06 | $390.00 | filing |
| 2026-03-19 | Moreadith Randall· Chief Scientific Officer | Sale | 39,000 | $2.50 | $97,500.00 | filing |
| 2026-03-19 | Moreadith Randall· Chief Scientific Officer | Option exercise | 39,000 | $0.06 | $2,340.00 | filing |
| 2026-02-02 | Moreadith Randall· Chief Scientific Officer | Sale | 6,500 | $3.03 | $19,680.05 | filing |
| 2026-02-02 | Moreadith Randall· Chief Scientific Officer | Option exercise | 6,500 | $0.06 | $390.00 | filing |
| 2026-01-28 | Moreadith Randall· Chief Scientific Officer | Sale | 6,500 | $3.57 | $23,185.50 | filing |
| 2026-01-28 | Moreadith Randall· Chief Scientific Officer | Option exercise | 6,500 | $0.06 | $390.00 | filing |
| 2026-01-22 | Moreadith Randall· Chief Scientific Officer | Sale | 2,500 | $2.95 | $7,375.00 | filing |
| 2026-01-22 | Moreadith Randall· Chief Scientific Officer | Option exercise | 2,500 | $0.06 | $150.00 | filing |
| 2026-01-21 | Moreadith Randall· Chief Scientific Officer | Sale | 2,000 | $3.00 | $6,000.00 | filing |
| 2026-01-21 | Moreadith Randall· Chief Scientific Officer | Option exercise | 2,000 | $0.06 | $120.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.